These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
70. [Progressive multifocal leukoencephalopathy and natalizumab-related immune reconstitution inflammatory syndrome: the advantage of MRI]. Gibelin N; Daelman L; Goulipian S; Wynckel A; Chaunu MP; Tourbah A Rev Neurol (Paris); 2014 Jan; 170(1):48-50. PubMed ID: 24139244 [No Abstract] [Full Text] [Related]
71. [Report of the 55th meeting of the American Academy of Neurology. Honolulu, March 29-April 6, 2003]. Becker H; Chochon F; de Toffol B; Defebvre L; Léger JM; Pierrot-Deseilligny C; Sellal F Rev Neurol (Paris); 2003 Apr; 159(4):470-86. PubMed ID: 12795263 [No Abstract] [Full Text] [Related]
72. Central nervous system white matter diseases other than multiple sclerosis. O'Riordan JI Curr Opin Neurol; 1997 Jun; 10(3):211-4. PubMed ID: 9229127 [TBL] [Abstract][Full Text] [Related]
74. Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in MS. Ko MY; Stefoski D; Balabanov R Neurology; 2011 Sep; 77(10):1020; author reply 1020. PubMed ID: 21893676 [No Abstract] [Full Text] [Related]
75. An open-label safety and drug interaction study of natalizumab (Antegren) in combination with interferon-beta (Avonex) in patients with multiple sclerosis. Vollmer TL; Phillips JT; Goodman AD; Agius MA; Libonati MA; Giacchino JL; Grundy JS Mult Scler; 2004 Oct; 10(5):511-20. PubMed ID: 15471366 [TBL] [Abstract][Full Text] [Related]
76. Devic's neuromyelitis optica: clinical and imaging findings. Vandevyver V; Lemmerling M; De Potter R; Verstraete K JBR-BTR; 2007; 90(4):284-7. PubMed ID: 17966247 [TBL] [Abstract][Full Text] [Related]
77. Natalizumab and progressive multifocal leukoencephalopathy: migrating towards safe adhesion molecule therapy in multiple sclerosis. Bennett JL Neurol Res; 2006 Apr; 28(3):291-8. PubMed ID: 16687056 [TBL] [Abstract][Full Text] [Related]
78. [Progressive multifocal leukoencephalopathy as a complication of natalizumab therapy]. Soilu-Hänninen M; Päivärinta M; Sonninen P; Parkkola R; Vuorinen T; Erälinna JP Duodecim; 2013; 129(7):765-70. PubMed ID: 23720945 [TBL] [Abstract][Full Text] [Related]
79. Treatment of progressive multifocal leukoencephalopathy associated with natalizumab. Wenning W; Haghikia A; Laubenberger J; Clifford DB; Behrens PF; Chan A; Gold R N Engl J Med; 2009 Sep; 361(11):1075-80. PubMed ID: 19741228 [TBL] [Abstract][Full Text] [Related]